REPORT HIGHLIGHT

Artificial Insemination market was valued at USD 1.63 billion by 2019, growing with 8.36 % CAGR during the forecast period, 2020-2026.

Artificial insemination is the process of insertion of sperm from the male either partner or donor into the female cervix or uterine cavity to achieve a pregnancy without sexual intercourse. It is a fertility treatment for humans, and animal breeding methods including dairy cattle, pigs, and many others. There are various methods of deploying the semen into the women’s womb for getting fertility in the female who wish to give birth to their own child and who may behave no relationship.

The most common method of artificial insemination in humans includes homologous (AIH) and donor semen (AID) is a treatment procedure used for many sub-fertile women across the globe. In animals, artificial insemination plays a vital role in the production of cows or bulls as it helps in the fulfillment of the dairy need of human beings. Artificial insemination in bull or other male animals into the female animal womb can help to produce more than 10 thousand or more calves annually from a single bull without a natural method.

Market Dynamics

The increased adoption of artificial insemination (AI) to have children in humans owing to surge in the infertility rates in the couples, is major factors boosting the growth of the global Artificial Insemination market. This is primarily due to low sperm count, premature ejaculation, and higher abnormal sperm motility. According to the report of the World Health Organization (WHO) in 2019, 8%–10% of couples in the world are being affected with infertility with an estimated around 60–80 million couples. Thus, the infertile people use the artificial treatment method for getting the pregnancy in women with a high concentration of sperm into the female reproductive tract to moderate male fertility problems. In addition, a rise in pharmaceutical companies for research & development expenditure of the various insemination kits has helped to grow the artificial insemination market. Furthermore, the rise in the number of Food and Drugs Authority (FDA) approval of the products related to artificial insemination all over the world is also an impelling factor for the overall growth.

Moreover, technological advancements in insemination techniques like the introduction of new intracytoplasmic sperm injection (ICSI) for child production which is implanted in the ovum of females create an eminent opportunity for this market. Furthermore, increasing the AI breeding programs with government initiatives for animal products around the world is likely to create lucrative growth opportunities in the worldwide market during the study period. For instance, in 2018, the government of the Central Kalimantan Province of Indonesia has implemented of Estrus Synchronization and Artificial Insemination Program (GBIB) in West Waringin Kota District for animal breeding to overcome the shortage of beef supply in their community.

Conversely, lack of professional healthcare for animal breeding and high risk of the infections, as well as the risk of birth defects occurring in the child for human reproductive are expected to hamper the market growth in the coming future. However, it is noted that this technology offers astounding benefits than in vitro fertilization, artificial insemination involves the insertion of sperm without the other expense.

Procedure Takeaway

In terms of procedure, the worldwide artificial insemination market is categorized into intracervical, intrauterine, intravaginal, and intratubal insemination. Out of these, the intrauterine insemination accounted for the majority of market share in 2019 and is anticipated to witness noteworthy growth during the forecast period. This is mainly due to the highest pregnancy rate provided with safe assistance due to the non-invasive method of childbirth across the globe.

In addition to this, segments like intracervical, and intratubal insemination are estimated to expand at the highest growth rate by the end of 2026 owing to increasing demand for the treatment and for having children as these methods also provide donor insemination along with the partner insemination.

Product Takeaway

In terms of products, the overall market is bifurcated into insemination kits, home conception devices, and accessories. Among these, insemination kits, and home conception devices played a leading role in 2019. The segment growth is attributed due to a surge in the prevalence of the infertility rate in the dominant region like North America. According to the Center for Disease Control and Prevention in 2018, the general fertility rate was 59.0 births per 1,000 women which were declined by 2% from 2017 with total estimated birth were 1,728.0 births per 1,000 women in the United States. This has created a huge demand for artificial insemination products like kits, accessories, and home conception devices during the future period in this region.

Source Takeaway

By source type, the global market is categorized into AIH-Husband, AID-Donor. The homologous husband (AIH) accounted for the largest market share in 2019 and is projected to grow exponentially during the study period. This growth is primarily owing to the donor is a husband and has a strong relationship with the mating women compare to other segments.

End-user Takeaway

Depending upon the end-user, the global market is classified into fertility centers, hospitals & clinics, and home care settings. Among which, the fertility centers have huge contribution for the growth of the artificial insemination market owing to the presence of a number of fertility center followed by hospitals & clinics segment for the new childbirth facility and infertility treatment method all over the world.

Regional Takeaway

Regionally, the overall market is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America is dominating region for the growth of artificial insemination market owing to the presence of the advanced technology, government support for the fertility insurance and growing awareness of the treatment method for infertility. According to the Centers for Disease Control and Prevention (CDC), around 1.7% of a child takes birth in the U.S. each year with the help of artificial insemination and by other means like assisted reproductive technology. The organization also stated that approximately 10 percent of the U.S. women of childbearing age have received treatment assistance for infertility. The treatment methods of infertility treatment include artificial insemination techniques and hormone therapy to stimulate egg production called assisted reproductive technology is fuelling the regional market growth. In addition to this, the fertility rate in the U.S. has also been declined. As per the Child Trend Organization in 2017, the fertility rate was estimated to around 60.3 births per 1,000 women, the lowest owing to the presence of a busy lifestyle in the U.S. followed by the European Region.

The Asia Pacific is projected to be the fastest-growing region throughout the study period owing to the growing population which requires the animals for dairy products as well as for the meeting the day-to-day food demand. Such factors are contributing to the regional market demand for artificial insemination in animals’ production, driving regional growth. In addition, the infertility rate in the huge population region like India, China has been also increasing factor for this market growth. For instance, as per the World Health Organization report in 2019, 15 and 20 million couples almost 25% of India alone has a prevalence of infertility rate. As per WHO, in the developing country, one in every four couples is affected by infertility. This factor also drives the growth of the artificial insemination market during the study period in this region.

COVID-19 Impact

The artificial insemination market is adversely affected due to the sudden outbreak of COVID-19 all over the globe. Artificial insemination was implemented in the human and animal due to the non-occurrence of the child and animal birth. This has drastically has been impacted due to the fear and issued certain guidelines to avoid the contact of corona-virus infection on a child’s birth all over the world. For example recently in 2020, the American Society of Reproductive Medicine (ASRM) has been suggested to stop new treatment method using intrauterine insemination (IUI), ovulation induction, and in vitro fertilization (IVF) for childbirth and has been issued new guidelines with the advice of its more than 8,000 members to avoid starting new treatment cycles.

Key Vendor Takeaway

The leading players of the global Artificial Insemination market includeRocket Medical, Kitazato Corporation, Conceivex Inc, Pride Angel, Tenderneeds Fertility, Rinovum Women’s Health, Genea Limited, Vitrolife, MedGyn Products Inc, INVO Bioscience, Hi-Tech Solutions, Fujifilm Irvine Scientific, and others.

Companies are actively involved in strategic joint ventures, mergers, and acquisitions to capture a large customer base. For example, in February 2019, INVO Bioscience has been entered into new distribution agreements to commercialize the invoice in vivo fertilization system in Africa. This acquisition helped the company to obtain a strong distribution and marketing of medical technologies in Africa, India, and the Middle East region.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2026
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

ARTIFICIAL INSEMINATION MARKET KEY PLAYERS

Rocket Medical
INVO Bioscience
Vitrolife
Pride Angel
Genea Limited
MedGyn Products, Inc.
Rinovum Women’s Health
Conceivex Inc
Tenderneeds Fertility
Hi-Tech Solutions
Fujifilm Irvine Scientific
Kitazato Corporation
ARTIFICIAL INSEMINATION MARKET, BY PROCEDURE

Intravaginal Insemination
Intrauterine Insemination
Intracervical Insemination
Intratubal Insemination
ARTIFICIAL INSEMINATION MARKET, BY PRODUCT TYPE

Home Conception Devices
Insemination Kits
Accessories
ARTIFICIAL INSEMINATION MARKET, BY SOURCE TYPE

AID-Donor
AIH-Husband
ARTIFICIAL INSEMINATION MARKET, BY END USER

Home Care Settings
Fertility Centers
Hospital & Clinics
ARTIFICIAL INSEMINATION MARKET, BY REGION

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA